Shares of SkinBioTherapeutics plc (LON:SBTX – Get Free Report) dropped 10.5% on Wednesday. The company traded as low as GBX 4 and last traded at GBX 4.25. 1,153,087 shares were traded during trading, a decline of 54% from the average session volume of 2,500,853 shares. The stock had previously closed at GBX 4.75.
SkinBioTherapeutics Price Performance
The company has a quick ratio of 10.01, a current ratio of 6.14 and a debt-to-equity ratio of 11.77. The firm has a market cap of £9.46 million, a PE ratio of -22.81 and a beta of 0.10. The stock has a 50 day moving average price of GBX 5.88 and a two-hundred day moving average price of GBX 9.23.
SkinBioTherapeutics Company Profile
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
Further Reading
- Five stocks we like better than SkinBioTherapeutics
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
